ADHD Predominantly Inattentive Type Clinical Trial
Official title:
Group-Based Cognitive-Behavioral Therapy for Adults With Attention-Deficit/Hyperactivity Disorder Inattentive Presentation: Randomized Controlled Trial
Verified date | March 2024 |
Source | Karolinska Institutet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Using a randomized controlled design, standard treatment of group cognitive-behavioral therapy (CBT) according to the Hesslinger protocol is compared to a newly developed group treatment specifically designed for adult patients with ADHD inattentive presentation (ADHD-I) called CBT for ADHD-I (CADDI). Research setting is psychiatric outpatient clinics. Research hypotheses include: 1. The CADDI protocol is more effective than standard treatment in terms of behavioral activation, procrastination, depressive symptoms, functional impairment, and quality of life, 2. Is equally effective in terms of ADHD symptoms, 3. Is more appreciated and tolerable, and 4. Outcome is mediated by mindful awareness. Effects are followed up at 6 and 12 months post treatment.
Status | Active, not recruiting |
Enrollment | 108 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Principal diagnosis of ADHD inattentive presentation 2. 18 years of age or older 3. If on medication, it needs to be well-established since three months, and 4. Prior psycho-educational intervention Exclusion Criteria: 1. Intellectual impairment 2. Substance use disorder 3. Difficulties in adherence to medical or other treatment 4. Social and/or psychiatric problems to such an extent that they prevent focusing on treatment, or 5. Simultaneous psychological treatment |
Country | Name | City | State |
---|---|---|---|
Sweden | Psychiatry Centre Södertälje | Södertälje | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Behavioral Activation for Depression Scale | Total score 0-150; higher scores represent increased activation | 14 weeks | |
Primary | Pure Procrastination Scale | Total score 12-60; higher scores represent more procrastination | 14 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03190902 -
Cognitive Impairment in Pediatric Onset Multiple Sclerosis
|
N/A | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Completed |
NCT01554046 -
The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT05452954 -
Psychosocial ADHD Interventions - Brief Parent Training
|
N/A | |
Recruiting |
NCT04504890 -
Ocular-vestibular Biomarker Identification for ADHD
|
||
Recruiting |
NCT06299189 -
A Therapist Guided Internet-delivered Treatment for Adults With ADHD (Attention Deficit / Hyperactivity Disorder) - an Open Effectiveness Trial in Routine Care
|
N/A | |
Recruiting |
NCT04729439 -
Technology-Enhanced Executive Functioning Intervention for ADHD
|
Phase 1 | |
Completed |
NCT01685281 -
Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder
|
Phase 2 |